High level expression of basic fibroblast growth factor having a homogeneous n-terminus
CA 2078875 C · Owner: California Biotechnology Inc. · Inventors: Thompson, Stewart A.; Abraham, Judith A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
DNA sequences are provided which encode a form of basic fibroblast growth factor lacking one of the alanine residues immediately following the N-terminal methionine residue of the primary translation product. The DNA sequences can be expressed to produce basic fibroblast growth factor having a homogeneous N-terminus.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 28, 1991 and granted February 26, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 28, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 28, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.